Evotec (EVO) to Release Quarterly Earnings on Wednesday

Key Points

• Evotec is expected to report Q4 2025 results on Wednesday, May 6, with analysts forecasting EPS ($0.1220) and $263.13 million in revenue.
• In the prior quarter the company reported $0.05 EPS and $297.02 million in revenue, but shows negative return on equity (12.4%) and a net margin of -13.13%; shares were trading around $2.97 with a one‑year range of $2.31–$4.80 and light volume.
• Analyst sentiment is a consensus Moderate Buy with an average target of $7.00 (three Buys, one Sell), and recent coverage includes Buy initiations from Berenberg and HC Wainwright.

Evotec (NASDAQ:EVO - Get Free Report) will likely be posting its Q4 2025 resultson Wednesday, May 6th. Analysts expect Evotec to post earnings of ($0.1220) per share and revenue of $263.1310 million for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, April 8, 2026 at 8:00 AM ET.

Evotec (NASDAQ:EVO - Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $297.02 million during the quarter. Evotec had a negative return on equity of 12.40% and a negative net margin of 13.13%. On average, analysts expect Evotec to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evotec Trading Down 0.5%

Shares of NASDAQ:EVO traded down $0.02 during trading on Wednesday, hitting $2.97. The company had a trading volume of 1,169 shares, compared to its average volume of 135,420. Evotec has a one year low of $2.31 and a one year high of $4.80. The company has a fifty day simple moving average of $2.88 and a two-hundred day simple moving average of $3.24. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.07 and a quick ratio of 1.99.

Institutional Investors Weigh In On Evotec

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its stake in shares of Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock worth $50,000 after acquiring an additional 4,600 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Evotec during the 4th quarter worth approximately $40,000. XTX Topco Ltd bought a new stake in shares of Evotec during the 2nd quarter worth approximately $66,000. Finally, HRT Financial LP bought a new stake in shares of Evotec during the 4th quarter worth approximately $72,000. 5.81% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Weiss Ratings raised Evotec from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday. Berenberg Bank assumed coverage on Evotec in a research note on Tuesday, February 3rd. They issued a "buy" rating for the company. Wall Street Zen raised Evotec from a "sell" rating to a "hold" rating in a research note on Saturday, January 10th. Finally, HC Wainwright assumed coverage on Evotec in a research note on Wednesday, April 15th. They issued a "buy" rating and a $7.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Evotec has a consensus rating of "Moderate Buy" and an average target price of $7.00.

About Evotec

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.